SUN Y7017, a treatment of Alzheimer’s Type Dementia to approved to launch in Japan
By Frontier India Pharmacetuicals News | February 8th, 2010 | Category: Asia Medical News | 1 Comment »
Daiichi Sankyo announced today that its subsidiary, ASUBIO PHARMA CO., LTD. (submitted a New Drug Application in Japan for the manufacturing and marketing of SUN Y7017 (generic name: Memantine hydrocholoride), which was developed for the treatment of Alzheimer’s type Dementia (AD).
SUN Y7017 is an N-methyl-D-aspartate (NMDA) receptor antagonist developed by Merz Pharmaceuticals GmbH (Head Office: Germany). This drug was approved for use in the treatment of AD by the European EMEA in 2002 and by the U.S. Food and Drug Administration in 2003. As of January 2010, this drug is marketed in more than 60 countries around the world, and is positioned as a standard care for AD.
By offering a new option with a distinct mechanism for the treatment of AD in Japan, Daiichi Sankyo expects to contribute to reducing the unmet needs of patients, their families, and medical professionals.
What’s the difference between dementia and Alzheimers? what is the difference? I think my father may be suffering one of these? does anyone know the warning signs? thanks